{"id":"NCT04602000","sponsor":"Celltrion","briefTitle":"A Phase 2/3 Study to Evaluate the Efficacy and Safety of CT-P59 in Patients With Mild to Moderate SARS-CoV-2 Infection","officialTitle":"A Phase 2/3, Randomized, Parallel-group, Placebo-controlled, Double-Blind Study to Evaluate the Efficacy and Safety of CT-P59 in Combination With Standard of Care in Outpatients With SARS-CoV-2 Infection","status":"COMPLETED","phase":"PHASE2","dates":{"start":"2020-10-05","primaryCompletion":"2021-05-21","completion":"2021-10-20","firstPosted":"2020-10-26","resultsPosted":"2022-07-20","lastUpdate":"2022-07-20"},"enrollment":1642,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["SARS-CoV-2 Infection"],"interventions":[{"type":"BIOLOGICAL","name":"CT-P59","otherNames":["regdanvimab"]},{"type":"BIOLOGICAL","name":"CT-P59","otherNames":["regdanvimab"]},{"type":"BIOLOGICAL","name":"Placebo","otherNames":[]},{"type":"BIOLOGICAL","name":"CT-P59","otherNames":["regdanvimab"]},{"type":"BIOLOGICAL","name":"Placebo","otherNames":[]}],"arms":[{"label":"CT-P59 40 mg/kg group (Part 1)","type":"EXPERIMENTAL"},{"label":"CT-P59 80 mg/kg group (Part 1)","type":"EXPERIMENTAL"},{"label":"Placebo group (Part 1)","type":"PLACEBO_COMPARATOR"},{"label":"CT-P59 40 mg/kg group (Part 2)","type":"EXPERIMENTAL"},{"label":"Placebo group (Part 2)","type":"PLACEBO_COMPARATOR"}],"summary":"This was a Phase 2/3 study to assess the efficacy about therapeutic effect of CT-P59 to the mild to moderate SARS-CoV-2 infected patients and the safety during after study drug injection.","primaryOutcome":{"measure":"Proportion of Patients With Clinical Symptom Requiring Hospitalization, Oxygen Therapy, or Experiencing Mortality Due to SARS-CoV-2 Infection (Part 1)","timeFrame":"Up to Day 28","effectByArm":[{"arm":"CT-P59 40 mg/kg Group (Part 1)","deltaMin":4,"sd":null},{"arm":"CT-P59 80 mg/kg Group (Part 1)","deltaMin":5,"sd":null},{"arm":"Placebo Group (Part 1)","deltaMin":9,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":1,"countries":["South Korea"]},"refs":{"pmids":["36043180","35713300","35295819","34473343"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":105},"commonTop":["Hypertriglyceridaemia","Alanine aminotransferase increased","Hepatic enzyme increased","Inflammatory marker increased","Hypertension"]}}